June 22, 2025
Operating Assets

With Trials In Motion, Cash To 2027, Can Kyverna’s Next Data Drop Turn The Stock Around? – Kyverna Therapeutics (NASDAQ:KYTX)

HC Wainwright upgraded Kyverna Therapeutics Inc. KYTX, citing three upcoming data sets through mid-2025. In its first quarter 2025 earnings released, the company highlighted: Enrollment is complete in the registrational Phase 2 KYV-101 trial for stiff person syndrome (SPS). The trial is on track for topline data and a biologics license application (BLA) filing is

Read More
Gold Investing

Gold Rally Could Gain Momentum With Central Bank Buying And China Allocation, Analyst Says – Barrick Gold (NYSE:GOLD)

BofA Securities analyst Lawson Winder discussed the performance of gold price last week and where it is headed. Gold prices have exceeded the analyst’s long-term target of $3,000 per ounce, with the analyst suggesting a potential rise to $3,500 if investment demand grows by 10%. China’s insurance sector could allocate up to 1% of its

Read More